Investigating a new treatment approach for IDH1-mutant glioma using p53 and ferroptosis.
Exploring p53-mediated ferroptosis to treat IDH1-mutant glioma
This study is looking at how changes in the p53 gene might affect treatment for a type of brain cancer called IDH1-mutant gliomas, and it hopes to find ways to make these tumors more responsive to a special kind of cell death that could help improve treatment options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11031338 on NIH RePORTER |
What this research studies
This research focuses on understanding how alterations in the p53 gene affect the treatment of IDH1-mutant gliomas, a type of brain cancer. The study aims to explore a specific form of cell death called ferroptosis, which may be inhibited by p53 alterations in these tumors. By reactivating p53, the researchers hope to make IDH1-mutant gliomas more sensitive to ferroptosis, potentially leading to more effective treatment strategies. Patients with this type of glioma may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with IDH1-mutant glioma.
Not a fit: Patients without IDH1 mutations or those with other types of brain tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that improve outcomes for patients with IDH1-mutant glioma.
How similar studies have performed: While the approach of targeting ferroptosis in gliomas is relatively novel, there is emerging evidence suggesting that similar strategies may have shown promise in other cancer types.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Huang, L. Eric — University of Utah
- Study coordinator: Huang, L. Eric
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.